Introduction
Although VPA is generally considered a safe medication in the elderly, 1 there are previous reports of patients developing reversible cognitive decline or reversible parkinsonism, often both. Common imaging findings among these reports are reversible cortical pseudoatrophy and enlargement of the lateral ventricles. 3, 4, 11, 13, 18, 20, 23 Here we describe an epilepsy patient treated with VPA for 15 years who presented to a Memory Disorders Clinic to be evaluated for normal pressure hydrocephalus due to a cognitive decline, gait changes, urinary incontinence, and ventriculomegaly on brain imaging. All clinical symptoms were reversed with cessation of VPA.
Case report
A 65-year-old woman with a generalized seizure disorder which began at age 25 presented to a Memory Disorders Clinic complaining of confusion. Medical records from the time of epilepsy diagnosis could not be obtained to further characterize her seizure type. After her first seizure she was treated with phenytoin for two years and subsequently had trials of monotherapy with Phenobarbital and carbamazepine. Since valproic acid (VPA) was initiated approximately at age 50 she has been seizure-free with an average daily dose of 1 g. No attempts of VPA discontinuation were made. At age 63, she gradually developed a gait disturbance, urinary incontinence, and worsening cognitive impairment that began affecting her normal functioning in her occupational and personal life over a two year period. Formal cognitive testing displayed significantly impaired memory ability as well as impaired executive function, visual perception, and a markedly slowed speed of mental information processing with intact language abilities. The remainder of her neurological examination was normal except for a moderately slow widebased gait with bilateral outward foot rotation requiring use of a walker.
Incidentally, the patient has a history of gradual hearing loss of unknown etiology starting in her early 50s. Her mother and maternal uncle also had a similar pattern of hearing loss. The same maternal uncle has a ''generalized seizure disorder'' of unknown etiology that started in his early 60s.
VPA blood levels were stable (78-85 mg/mL) and within the therapeutic range. An ammonia level was normal (30 mmol/L). A brain MRI revealed mild prominence of the lateral ventricles concerning for normal pressure hydrocephalus, however significant sulcal atrophy was also observed. Given the apparent dementia, urinary incontinence, gait changes, and an MRI suggestive of enlarged ventricles, a workup for normal pressure hydrocephalus was pursued. A large volume lumbar puncture (29 mL of CSF was expressed) did not benefit gait or cognitive measures. During the procedure the patient developed a severe positional headache. CSF studies were normal with no evidence of infection or inflammation. CSF levels of Ab42 (491.4 pg/mL) and phosphorylated-tau (32.35 pg/mL) were not consistent with Alzheimer's disease. An FDG PET scan revealed hypometabolism in the bilateral periventricular regions, right anterior parietal region, and few small scattered areas of decreased metabolic activity in the right frontal region. This pattern is not consistent with Alzheimer's disease. VPA was changed to levetiracetam without incident. Cognition and gait disturbance gradually normalized over the following two months. A brain MRI 4 months after cessation of VPA showed possible reduction of ventricular size (see Table 1 ). On 3 out of 4 measures of ventricle size, numeric reductions were seen 4 months after cessation of VPA. The ventricular measurements were performed by a radiologist blinded to the clinical history.
Discussion
Our patient gradually developed dementia symptoms and a gait disturbance after 15 years of VPA use. About two months after discontinuation of VPA, her cognition and gait returned to normal, implicating a VPA-induced syndrome. Although she also presented with urinary incontinence, it appears due to an unrelated urologic disorder.
A possible mechanistic explanation involves inhibition of neurite outgrowth. Using SY5Y neuroblastoma cells as a neuronal model, Qian et al. found that therapeutic plasma levels of VPA reduced cell proliferation and neurite outgrowth. 24 VPA also reduced mRNA and protein levels of neurofilament 160 (NF160). These effects were reversed after 2 days of cessation of VPA exposure. GABA pathway disturbance leading to dopamine inhibition has also been hypothesized. 16 Evidence indicates that GABA mediates dopaminergic function in the substantia nigra. 25 VPA or a metabolite of VPA such as delta-2-valproate, which may be a more potent inhibitor of the human brain GABA-degrading enzyme than VPA, 26 may cause a transient inhibitory effect on dopaminergic pathways. Another proposed mechanism of the reversible cognitive decline seen in these patients taking VPA is a mitochondrial DNA (mtDNA) mutation. Since VPA enters mitochondrial metabolism pathways, a clinically silent mutation could become overt when a new drug or drug metabolite is introduced. 27 One of the reported cases of VPA-induced non-hyperammonemic reversible cognitive decline describes a pediatric patient who was found to have a C8393TT-Pro!Ser mutation in the MTATP8 gene. 3 Such a mutation could explain the idiosyncratic nature of this drug side effect. Also, since mtDNA mutations are heteroplasmic, it would explain the highly variable clinical timeline of symptom appearance. It is possible that our patient's hearing loss and epilepsy are all related to an undiagnosed mtDNA mutation syndrome, which is supported by the family history of idiopathic generalized seizures and hearing loss that follows a pattern of maternal inheritance. In our patient, genetic testing was not performed. VPA-induced reversible sensorineural hearing loss has also been reported, 28 but cessation of VPA had no effect on hearing in our patient.
Conclusion
This case exemplifies the adverse effects of VPA, which can cause neurological symptoms even in long-term treated patients. Clinicians should be aware of how valproate-induced pseudoatrophy with cognitive impairment and parkinsonian features can masquerade as dementia syndromes such as Alzheimer's disease or normal pressure hydrocephalus. Recognizing this clinical scenario can allow clinicians to avoid unnecessary tests or treatments, and most importantly, to possibly reverse the condition. 
